Taking the potent impact of these non-angiogenic processes in cancer progression into consideration, may help us explain the occurring resistance of lung tumors to VEGF-inhibitors (Döme et al., 2007; Bergers and Hanahan, 2008). This evidence concerns the gene VEGFA and cancer.